To present a framework within which population pharmacokinetic (PPK) studies should be designed and analyzed and discuss the application of developed PPK models.
METHODS
Information on PPK was retrieved from a MEDLINE search (1979–December 2003) of the literature and a bibliographic evaluation of review articles and books. This information is used in conjunction with experience to explain the design and analysis of PPK studies. Also, examples are included to demonstrate the usefulness of PPK.
SYNTHESIS
A great deal of thought must be given to the design and analysis of PPK studies (ie, development of PPK models). Models are of 2 primary types—descriptive and predictive—and the process applied to these models is necessarily different. An approach that ensures model applicability is presented.
CONCLUSIONS
PPK models have great utility, and the applications are many. They are very different from single-subject pharmacokinetic models and therefore require different approaches to model estimation.
. EtteEI, WilliamsPJ. Population pharmacokinetics. I: background, concepts, and models. Ann Pharmacother2004; 38: 1702–6. DOI 10.1345/aph.1D374
2.
. EtteEI, WilliamsPJ. Population pharmacokinetics. II: estimation methods. Ann Pharmacother2004; 38: 1907–15. DOI 10.1345/aph.1E259
3.
. EtteEI, WilliamsP, FadiranE, AjayiFO, OnyiahLC. The process of knowledge discovery from large pharmacokinetic data sets. J Clin Pharmacol2001; 41: 25–34.
4.
. EtteEI, WilliamsPJ, KimYH, LaneJR, LiuMJ, CapparelliEV. Model appropriateness and PPK modeling. J Clin Pharmacol2003; 43: 610–23.
5.
. EtteEI, SunH, LuddenTM. Design of population pharmacokinetic studies. Proc Am Stat Assoc1994; 487–92.
6.
. JonesCD, SunH, EtteEI. Designing cross-sectional pharmacokinetic studies: implications for pediatric and animal studies. Clin Res Regul Affairs1996; 13: 133–65.
7.
. FadiranEO, JonesCD, EtteEI. Designing population pharmacokinetic studies: performance of mixed designs. Eur J Drug Metab Pharmacokinet2000; 25: 231–9.
8.
. Guidance for industry: population pharmacokinetics. Rockville, MD: Food and Drug Administration, Department of Health and Human Services, 1999.
9.
. GraselaTH, AntalEJ, Fiedler-KelleyJ, FoitDJ, BarthB, KnuthDW, An automated drug concentration screening and quality assurance program for clinical trials. Drug Info J1999; 33: 273–9.
10.
. EtteEI. Statistical graphics in pharmacokinetics and pharmacodynamics: a tutorial. Ann Pharmacother1998; 32: 818–28. DOI 10.1345/aph.17304
11.
. EtteEI, LuddenTM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res1995; 12: 1845–55.
12.
. SheinerLB, LuddenTM. Population pharmacokinetics. Annu Rev Pharmacol Toxicol1992; 32: 185–209.
13.
. KarlssonMO, SheinerLB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm1993; 21: 735–50.
14.
. SidhuJS, AshtonM, HuongNV, HaiTN, KarlssonMO, SyND, Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol1998; 45: 347–54.
15.
. SunH, FadiranEO, JonesCD, LeskoL, HuangSM, HigginsK, Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet1999; 37: 41–58.
16.
. Al-BannaMK, KelmanAW, WhitingB. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm1990; 18: 347–60.
17.
. BonatePL. Clinical trial simulation in drug development. Pharm Res2000; 17: 252–6.
18.
. HaleM, GillespieWR, GuptaSK, TukB, HolfordNH. Clinical trial simulation: streamlining your drug development process. Appl Clin Trials1996; 5: 35–40.
19.
. JohnsonNE, WadeJR, KarlssonMO. Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm1996; 24: 245–72.
20.
. KowalskiKG, HutmacherMM. Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med2001; 20: 75–91.
. EtteEI, KelmanAW, HowieCA, WhitingB. Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm1995; 23: 551–66.
23.
. RubinDB. Multiple imputation after 18+ years. J Am Stat Assoc1996; 91: 473–89.
24.
. RubinDB. Inference and missing data. Biometrika1976; 63: 581–2.
25.
. EtteEI, KelmanAW, HowieCA, WhitingB. Efficient experimental design and estimation of population pharmacokinetic parameters in preclinical animal studies. Pharm Res1995; 12: 729–37.
26.
. MillerRG. The jackknife: a review. Biometrika1974; 61: 1–15.
27.
. HinkleyDV. Jackknife confidence limits using Student t approximations. Biometrika1977; 64: 21–8.
28.
. EfronB, GongG. A leisurely look at the bootstrap, the jackknife and cross validation. Am Statistician1983; 37: 36–48.
29.
. EtteEI. Population model stability and performance. J Clin Pharmacol1997; 37: 486–95.
30.
. BoxGEP. Robustness in the strategy of scientific model building. In: LaurerRL, WilkinsonGN, eds. Robustness in statistics. New York: Academic Press, 1979: 201–36.
. EtteEI, OnyiahLC. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with winsorization. Eur J Drug Metab Pharmacokinet2002; 27: 213–24.
34.
. WilliamsPJ, EtteEI. Determination of model appropriateness. In: KimkoHC, DuffilS, eds. Clinical trial simulations. New York: Marcel Dekker, 2002: 73–104.
35.
. GelmanA, MengXL, SternH. Posterior predictive assessment of model fitness via realized discrepancies. Statistica Sinica1996; 6: 733–807.
36.
. DufullSB, ChabaudS, NonyP, GirardP, AaronsL. A pharmacokinetic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci2000; 10: 285–95.
37.
. DufullSB, AaronsL. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci2000; 10: 275–84.
38.
. YanoH, BealSL, SheinerLB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodynam2001; 28: 171–91.
39.
. MentreF, EbelenME. Validation of population pharmacokinetic–pharmacodynamic analyses: review of proposed approaches. In: BalantLP, AaronsL, eds. The population approach: measuring and managing variability in response concentration and dose (COST B1). Brussels: Office for Official Publications of the European Communities, 1997: 146–60.
40.
. WilliamsPJ, LaneJR, CapparelliEC, KimYH, ColemanRB. Direct comparison of three methods for predicting digoxin concentrations. Pharmacotherapy1996; 16: 1085–92.
41.
. VozehS, MaitrePO, StanskiDR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm1990; 18: 161–73.
42.
. BrunoR, VivlerN, VergniolJC, De PhillipsSL, MontayG. SheinerLB. A population pharmacokinetic model for docetaxel (taxotere): model building and validation. J Pharmacokinet Biopharm1996; 24: 153–72.
43.
. SteimerJL, VozehS, Racine-PoonA, HolfordN, O'NeilR. The population approach: rationale, methods, and applications in clinical pharmacology and drug development. In: WellingPG, BalantLP, eds. Pharmacokinetics of drugs (handbook of experimental pharmacology). Berlin-Heidelberg: Springer-Verlag, 1994; 110: 404–51.
44.
. SamaraE, GranneR. Role of pharmacokinetics in drug development: a pharmaceutical industry perspective. Clin Pharmacokinet1997; 32: 294–312.
45.
. WhitingB, KelmanAW, GrevelJ. Population pharmacokinetics: theory and clinical application. Clin Pharmacokinet1986; 11: 387–401.
46.
. OlsenSC, BockbraderH, BoydRA, CookJ, KoupJR, LalondeRL, Impact of population pharmacokinetic–pharmacodynamic analyses on the drug development process. Clin Pharmacokinet2000; 38: 449–59.
47.
. EtteEI, MillerR, GillespieWR, HuangSM, LeskoL, WilliamsR. The population approach: FDA experience. In: AaronsL, BalantLP, DanhofM, Gex-FabryM, Gundert-RemyVA, KarlssonMO, eds. The population approach: measuring and managing variability in response, concentration and dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research, 1997: 271–5.
48.
. PeckCC. Population approach in pharmacokinetics and pharmacodynamics: FDA view. In: RowlandM, AaronsL, eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Commission of the European Communities, 1992: 157–68.
49.
. HossainM, WrightE, BawejaR, LuddenTM, MillerR. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and controlled release (CR) dosage form of alpazolam. Pharm Res1997; 14: 309–15.
50.
. HolfordNHG, AmbrosRJ, StoeckelK. Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm1992; 20: 421–42.
51.
. KaniwaN, AoyagiN, OgataH, IshiM. Application of the NONMEM method to the evaluation of the bioavailability of drug products. J Pharm Sci1990; 79: 1116–20.
52.
. GravesDA, ChangI. Application of NONMEM to routine bioavailability data. J Pharmacokinet Biopharm1990; 2: 145–60.
53.
. KarlssonMO, SheinerLB. Estimating bioavailability when clearance varies with time. Clin Pharmacol Ther1994; 55: 623–37.
54.
. PentikisHS, HendersonJD, TranNL, LuddenTM. Bioequivalence: individual and population compartmental modeling compared to the non-compartmental approach. Pharm Res1996; 13: 1116–21.
55.
. ParkK, VerottaD, BlaschkeTF, SheinerLB. A semiparametric method for describing noisy population pharmacokinetic data. J Pharmacokinet Biopharm1997; 25: 615–42.
